{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-090170","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.297903+00:00","generated_at":"2026-05-18T17:58:36.202450+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"CRISPR Therapeutics reports up to 86% LDL reduction with CTX310; delays CTX320 data to H1 2026","bullets":["CTX310 Phase 1 shows up to 82% TG and 86% LDL reductions at 0.8 mg/kg with stable liver enzymes.","CTX320 (LPA gene) Phase 1 data update expected in first half of 2026 due to strategic pause for Lp(a) landscape insights.","CTX340 (AGT gene) for refractory hypertension advancing through IND/CTA-enabling studies.","CTX310 trial enrolling HoFH, severe hypertriglyceridemia, HeFH, and mixed dyslipidemia patients."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-090170","json":"https://secwatch.observer/filing/0000950170-25-090170.json","markdown":"https://secwatch.observer/filing/0000950170-25-090170.md","text":"https://secwatch.observer/filing/0000950170-25-090170.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017025090170/0000950170-25-090170-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017025090170/crsp-20250626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:58:36.202450+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}